María de Jesús Loera-Arias

Dr. María de Jesús Loera-Arias

Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, Mexico

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
Ana DuarteAna Duarte
Ana Duarte
YGYareth Gopar-Cuevas
Yareth Gopar-Cuevas
OSOdila Saucedo-Cárdenas
Odila Saucedo-Cárdenas
MLMaria Loera-Arias
Maria Loera-Arias
RLRoberto Montes de Oca Luna
Roberto Montes de Oca Luna
HRHumberto Rodríguez-Rocha
Humberto Rodríguez-Rocha
Oxidative stress is considered one of the pathological mechanisms that cause Parkinson’s disease (PD), which has led to the investigation of several antioxidants molecules as a potential therapeutic treatment against the disease. Although preclinical studies have demonstrated the efficacy of these compounds to maintain neuronal survival and activity in PD models, these results have not been reflected in clinical trials, antioxidants have not been able to act as disease modifiers in terms of clinical symptoms. Translational medicine currently faces the challenge of redesigning clinical trials to standardize criteria when testing molecules to reduce responses’ variability. Herein, we discuss current challenges and opportunities regarding several non-enzymatic antioxidants’ therapeutic molecules for PD patients’ potential treatment.

3 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DMDavid Hernán Martínez-Puente
David Hernán Martínez-Puente
JPJose Juan Perez-Trujillo
Jose Juan Perez-Trujillo
LZLaura Mireya Zavala-Flores
Laura Mireya Zavala-Flores
AGARACELY GARCIA-GARCIA
ARACELY GARCIA-GARCIA
AVArnulfo Villanueva-Olivo
Arnulfo Villanueva-Olivo
MLMaria Loera-Arias
Maria Loera-Arias
Recently, the interest in using nucleic acids for therapeutic applications has been increasing. DNA molecules can be manipulated to express a gene of interest for gene therapy applications or vaccine development. Plasmid DNA can be developed to treat different diseases, such as infections and cancer. In most cancers, the immune system is limited or suppressed, allowing cancer cells to grow. DNA vaccination has demonstrated its capacity to stimulate the immune system to fight against cancer cells. Furthermore, plasmids for cancer gene therapy can direct the expression of proteins with different functions, such as enzymes, toxins, and cytotoxic or proapoptotic proteins, to directly kill cancer cells. The progress and promising results reported in animal models in recent years have led to interesting clinical results. These DNA strategies are expected to be approved for cancer treatment in the near future. This review discusses the main strategies, challenges, and future perspectives of using plasmid DNA for cancer treatment.

1 December 2016 in Toxicology in Vitro
Verified
Journal Article
Closed access
SES.C. Esparza-González
S.C. Esparza-González
SSS. Sánchez-Valdés
S. Sánchez-Valdés
SRS.N. Ramírez-Barrón
S.N. Ramírez-Barrón
MLMaria Loera-Arias
Maria Loera-Arias
JBJ. Bernal
J. Bernal
Rebeca Betancourt GalindoRebeca Betancourt Galindo
Rebeca Betancourt Galindo

5 August 2023 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
YGYareth Gopar-Cuevas
Yareth Gopar-Cuevas
OSOdila Saucedo-Cárdenas
Odila Saucedo-Cárdenas
MLMaria Loera-Arias
Maria Loera-Arias
RLRoberto Montes de Oca Luna
Roberto Montes de Oca Luna
HRHumberto Rodríguez-Rocha
Humberto Rodríguez-Rocha
AGARACELY GARCIA-GARCIA
ARACELY GARCIA-GARCIA

13 June 2019 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
MRMarcela J. Ramirez-Moreno
Marcela J. Ramirez-Moreno
ADAna P. Duarte-Jurado
Ana P. Duarte-Jurado
YGYareth Gopar-Cuevas
Yareth Gopar-Cuevas
AGAlfredo Gonzalez-Alcocer
Alfredo Gonzalez-Alcocer
MLMaria Loera-Arias
Maria Loera-Arias
AGARACELY GARCIA-GARCIA
ARACELY GARCIA-GARCIA

6 November 2019 in Nanomaterials
Verified
Journal Article
Open access
PDF file
DSDaniel Salas-Treviño
Daniel Salas-Treviño
OSOdila Saucedo-Cárdenas
Odila Saucedo-Cárdenas
MLMaria Loera-Arias
Maria Loera-Arias
HRHumberto Rodríguez-Rocha
Humberto Rodríguez-Rocha
AGAracely García-García
Aracely García-García
ASAdolfo Soto-Domínguez
Adolfo Soto-Domínguez
Carbon nanotubes (CNTs) have emerged in recent years as a potential option for drug delivery, due to their high functionalization capacity. Biocompatibility and selectivity using tissue-specific biomolecules can optimize the specificity, pharmacokinetics and stability of the drug. In this study, we design, develop and characterize a drug nanovector (oxCNTs-HA-CPT) conjugating oxidated multi-wall carbon nanotubes (oxCNTs) with hyaluronate (HA) and carboplatin (CPT) as a treatment in a lung cancer model in vitro. Subsequently, we exposed TC–1 and NIH/3T3 cell lines to the nanovectors and measured cell uptake, cell viability, and oxidative stress induction. The characterization of oxCNTs-HA-CPT reveals that on their surface, they have HA. On the other hand, oxCNTs-HA-CPT were endocytosed in greater proportion by tumor cells than by fibroblasts, and likewise, the cytotoxic effect was significantly higher in tumor cells. These results show the therapeutic potential that nanovectors possess; however, future studies should be carried out to determine the death pathways involved, as well as their effect on in vivo models.